- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Investigational T-cell engager (TCE) therapies utilize antibodies engineered to contain multiple binding domains, designed to specifically and simultaneously recognize T cells and antigen-expressing target cells.1,2 This dual binding brings the two cells in close proximity, facilitating cross-linking, which is proposed to result in T-cell activation and cytokine release, followed by cytolytic synapse formation, secretion of cytolytic enzymes, and subsequent cell death.1,2 Surface antigen binding domains, such as B-cell maturation antigen (BCMA) domains, allow for targeting with specific affinity for BCMA-expressing cells, including multiple myeloma cells.1,2 A T-cell binding domain, such as a CD3 domain, allows for specific targeting of T cells and their subsequent activation.1 Autoimmunity is potentially decreased by silencing the Fc region of TCE antibodies, to potentially reduce interactions with innate immune cells and reduce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) induction.1-3 The silenced Fc region retains immunoglobulin-like pharmacokinetic properties and the capacity to bind to FcRn.3,5 Preclinical studies suggest that TCEs bypass the immune system’s need for antigen presentation by the major histocompatibility complex (MHC) and can directly target antigen-expressing cells.1,4Preclinical studies of the benefits and risks of TCEs are ongoing, including development of an investigational anti-BCMA 2 + 1 TCE for treatment of relapsed/refractory multiple myeloma.1,2,5